Paushak Ltd – ₹1,844 Cr Market Cap, Phosgene Kingpin Playing Chemistry with Investors
1. At a Glance
Welcome to Paushak Ltd, the company where poison gas meets shareholder confusion. With a market cap of ~₹1,844 Cr and share price at ₹5,984, this Alembic Group offspring proudly calls itself India’s largest phosgene-based specialty chemicals maker. Translation: they sell dangerous gases wrapped in EBITDA margins. Despite OPM at 30%+, sales growth has been crawling slower than your home WiFi on JioFiber peak hours. To spice it up, the CEO resigned in April 2025, board promptly reshuffled, and a 2-for-1 split + 3:1 bonus issue is coming—because when you can’t grow sales, you grow share certificates.
2. Introduction
Founded as part of Alembic’s empire, Paushak is one of those niche specialty chemical firms: small, profitable, but forever in the shadows of its bigger chemical cousins. It makes chloroformates, isocyanates, chlorides, carbamates—basically things that sound like chemistry viva answers and smell like danger.
On paper:
Margins: Fat (30% OPM).
Debt: Negligible (₹25 Cr).
Promoter holding: 67%.
Book value: ₹1,510 per share.
But then:
Sales growth last 5 years? ~9%. Even your FD interest rate grew faster.
ROE? Barely 10%. That’s what even PSU banks manage on a good monsoon.
Profit CAGR 5 years? ~6%. A lethargic compounder.
So why ₹6,000 per share? Because niche + Alembic halo + market’s obsession with anything “specialty chemical.”
3. Business Model – WTF Do They Even Do?
Paushak is the chemical industry’s Walter White. Instead of meth, they specialize in phosgene chemistry—a compound infamous from WWI as a toxic gas, now sanitized for pharma and agro use.
Chlorides, Carbonates, Carbamates – used in dyes, plastics, pesticides.
Custom Manufacturing – niche molecules on contract.
Customers? Pharma, agrochemicals, dyes, plastics, perfumery. So, your cough syrup, mosquito spray, and even that Axe body spray might have Paushak DNA in them.
Problem: The business is so niche that scalability is tough. You can’t just open a new phosgene plant next to your society garden. Hence, sales growth = crawling.
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
₹55.9 Cr
₹52.0 Cr
₹52.0 Cr
+7.4%
+7.5%
EBITDA
₹18.0 Cr
₹14.0 Cr
₹16.0 Cr
+28.6%
+12.5%
PAT
₹12.0 Cr
₹10.3 Cr
₹10.0 Cr
+16.7%
+20.0%
EPS (₹)
39.0
33.5
31.2
+16.4%
+25.0%
Commentary: Stable revenues, improving profitability. But EPS annualized (~₹166) → P/E ~36x. Paying Nestlé valuations for a company that grows like Doordarshan viewership.
5. Valuation – Fair Value Range Only
P/E Method
EPS TTM: ₹166
Industry PE: 30–35
Fair Value = ₹166 × 30–35 = ₹4,980–₹5,810
EV/EBITDA
EBITDA TTM: ~₹77 Cr
EV: ₹1,869 Cr
EV/EBITDA: 24.2 (vs peers 15–20)
Fair EV: ₹1,200–₹1,500 Cr → Equity value: ₹3,800–₹4,700 per share
DCF (napkin math)
Assume FCF ~₹40 Cr, growth 8%, WACC 11%
Fair Value: ₹4,500–₹5,500
Fair Value Range: ₹3,800–₹5,500 (Educational only. Not SEBI-approved stock tips.)
6. What’s Cooking – News, Triggers, Drama
Corporate Masala: CEO Abhijit Joshi resigned April 2025. Chintan Gosaliya parachuted in. Nothing screams stability like frequent CEO musical chairs.
Bonus + Split: 2-for-1 split + 3:1 bonus issue approved. Basically, 1 share becomes 6. Because if sales won’t grow, let’s at least grow paper wealth.
Capex: Raised borrowing limit to ₹750 Cr. Will they
